International Journal of Hematology最新文献_第5页

Response to initial treatment with glucocorticoids in TAFRO syndrome and implications for secondary treatment.

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-29 DOI: 10.1007/s12185-025-03933-1

Ryutaro Tominaga, Kento Umino, Seina Honda, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-Ichiro Fujiwara, Yoshinobu Kanda

{"title":"Response to initial treatment with glucocorticoids in TAFRO syndrome and implications for secondary treatment.","authors":"Ryutaro Tominaga, Kento Umino, Seina Honda, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-Ichiro Fujiwara, Yoshinobu Kanda","doi":"10.1007/s12185-025-03933-1","DOIUrl":"https://doi.org/10.1007/s12185-025-03933-1","url":null,"abstract":"The study aimed to investigate the therapeutic effect of various initial treatments incorporating glucocorticoid (GC) in TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly). Cases of TAFRO syndrome up to November 2023 were retrospectively collected. Overall survival (OS) and resistance to GC therapy were assessed, with resistance analyzed based on the time to the next treatment or death (TTNTD). The study included 95 patients, including 5 diagnosed at our hospital. OS did not differ significantly between patients who received GC monotherapy and those who had a second-line therapy added within 2 weeks (100-day OS rate: 86.6% vs. 77.7%; p = 0.338). Moreover, 100-day OS did not differ between patients who received GC pulse therapy within 2 weeks and those who did not (77.5% vs. 93.1%, p = 0.129). In multivariate analyses, pretreatment severity score ≥ 8 (hazard ratio [HR], 2.99; 95% confidence interval [CI] 1.05-8.50) and platelets ≥ 6.9 × 10^4/µL (HR, 2.26; 95% CI 1.01-5.02) were significantly associated with shorter TTNTD. Additional second-line or GC pulse therapy provided no advantage in the hyperacute phase. Higher severity scores and platelet values may predict resistance to GC therapy.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-28 DOI: 10.1007/s12185-025-03924-2

Masataka Kuwana, Yoshiaki Tomiyama

引用次数: 0

Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-23 DOI: 10.1007/s12185-025-03915-3

Lin-Sen Feng, Hui-Yuan Li, Ai Tang, Meng-Li Xu, San-Bin Wang

{"title":"Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.","authors":"Lin-Sen Feng, Hui-Yuan Li, Ai Tang, Meng-Li Xu, San-Bin Wang","doi":"10.1007/s12185-025-03915-3","DOIUrl":"https://doi.org/10.1007/s12185-025-03915-3","url":null,"abstract":"Background: The treatment of relapsed/refractory T cell acute lymphoblastic leukemia (R/R T-ALL) is a significant challenge in hematologic oncology, and no standard salvage treatment plan exists. Both Chinese and international clinical guidelines recommend combination chemotherapy including venetoclax.Methods: Efficacy and safety of venetoclax, azacitidine, homoharringtonine, cytarabine, and aclarubicin (VA-HAA) combination therapy were retrospectively analyzed in 3 patients with R/R T-ALL at the Department of Hematology, 920th Hospital of the Joint Logistics Support Force, Chinese People's Liberation Army.Results: The chemotherapy resulted in CR/CRi with negative flow MRD in all 3 patients. Quantitative negative conversion was achieved in 2 patients with fusion genes, and the frequency of monoclonal TCR gene rearrangements was significantly reduced in 1 patient. All patients received stem cell rescue after the chemotherapy. Hematologic toxicity may be manageable, with a median of 24 days for complete recovery of neutrophils (ANC) and 36 days for partial recovery of platelets. There were no major bleeding events or chemotherapy-related deaths.Conclusion: VA-HAA may be an effective and safe salvage treatment for R/R T-ALL, and prospective clinical trials are needed to verify its specific clinical efficacy.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The medium-fluorescence reticulocyte ratio is an independent predictor of G6PD deficiency neonates. 中荧光网状细胞比率是G6PD缺乏症新生儿的独立预测因子。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-21 DOI: 10.1007/s12185-025-03916-2

Mingliang Rao, Wenna Luo, Baojing Wu

{"title":"The medium-fluorescence reticulocyte ratio is an independent predictor of G6PD deficiency neonates.","authors":"Mingliang Rao, Wenna Luo, Baojing Wu","doi":"10.1007/s12185-025-03916-2","DOIUrl":"https://doi.org/10.1007/s12185-025-03916-2","url":null,"abstract":"Objective: G6PD deficiency is a potentially life-threatening condition in neonates presenting with hyperbilirubinemia. This study aims to identify clinical and laboratory predictors of G6PD deficiency in neonates presenting with hyperbilirubinemia.Methods: This was a retrospective study of 227 term neonates admitted to Heyuan People's Hospital from January 2019 to October 2023. Hematological parameters and bilirubin were compared between those with G6PD deficiency and those with normal G6PD.Results: Term neonates with G6PD deficiency had higher levels of total bilirubin, indirect bilirubin, mean corpuscular volume, mean corpuscular hemoglobin, immature reticulocyte fraction, high-fluorescence reticulocyte ratio, medium-fluorescence reticulocyte ratio, and content of reticulocytes than those with normal G6PD, but lower levels of red blood cells, hemoglobin, hematocrit, and low-fluorescence reticulocyte ratio. Medium-fluorescence ratios (OR = 1.291, P = 0.028) independently predicted G6PD deficiency in neonates. The optimal cut-off value for medium-fluorescence ratios was > 18.55%. The area under the curve for diagnosing G6PD deficiency was 0.924 (95% confidence interval: 0.886-0.962, P < 0.0001), with a sensitivity of 82.6% and specificity of 86.2%.Conclusion: MFR emerged as a potentially valuable predictor for G6PD deficiency in neonates.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ixazomib-induced angioedema. Ixazomib-induced血管性水肿。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-21 DOI: 10.1007/s12185-025-03919-z

Katsuro Ito, Naohiko Aozasa

引用次数: 0

Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance. 移植后Ph+ ALL的tki：迄今为止的实践和临床意义。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-17 DOI: 10.1007/s12185-025-03917-1

Satoshi Nishiwaki, Seitaro Terakura, Takanobu Morishita, Tatsunori Goto, Yuichiro Inagaki, Kotaro Miyao, Nobuaki Fukushima, Daiki Hirano, Naoyuki Tange, Shingo Kurahashi, Yachiyo Kuwatsuka, Masanobu Kasai, Hiroatsu Iida, Kazutaka Ozeki, Masashi Sawa, Tetsuya Nishida, Hitoshi Kiyoi

{"title":"Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.","authors":"Satoshi Nishiwaki, Seitaro Terakura, Takanobu Morishita, Tatsunori Goto, Yuichiro Inagaki, Kotaro Miyao, Nobuaki Fukushima, Daiki Hirano, Naoyuki Tange, Shingo Kurahashi, Yachiyo Kuwatsuka, Masanobu Kasai, Hiroatsu Iida, Kazutaka Ozeki, Masashi Sawa, Tetsuya Nishida, Hitoshi Kiyoi","doi":"10.1007/s12185-025-03917-1","DOIUrl":"https://doi.org/10.1007/s12185-025-03917-1","url":null,"abstract":"Post-transplant tyrosine kinase inhibitors (TKIs) show promise in preventing relapse after allogeneic hematopoietic cell transplantation (allo-HCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). However, their real-world use and efficacy remain unclear. A comprehensive study across seven centers included Ph+ALL patients who underwent allo-HCT between 2002 and 2022. Post-transplant TKIs were administered in 28% of patients (49 of 173 transplanted in complete remission): 7% as prophylaxis during complete molecular remission (CMR), and 21% in response to measurable residual disease (MRD) positivity. Median first post-transplant TKI duration was 13.7 months for the prophylactic group and 4.0 months for the MRD-triggered group. Prophylactic TKIs appear particularly beneficial for patients not in CMR at allo-HCT, showing a trend towards higher 5-year relapse-free survival (RFS) compared to those not receiving prophylactic TKIs (100% vs. 73%; P = 0.11). Significant RFS differences were observed between the prophylactic, non-TKI, and MRD-triggered groups. However, patients with white blood cell counts <15000/µl at diagnosis and no additional chromosomal abnormalities-an MRD-triggered high efficacy cluster-demonstrated comparable 5-year RFS regardless of TKI strategy (100% vs. 85% vs. 80%; P = 0.87). This cluster highlights the potential effectiveness of MRD-triggered TKI administration in select low-risk patients, suggesting tailored TKI strategies based on risk factors.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS). 2023年JSH血液恶性肿瘤实用指南：白血病-6。骨髓增生异常综合征（MDS）。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-14 DOI: 10.1007/s12185-024-03906-w

Yasushi Miyazaki

引用次数: 0

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities. 日本2024弥散性血管内凝血管理临床实践指南第三部分：实体癌和血管异常。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-10 DOI: 10.1007/s12185-024-03912-y

Yoshinobu Seki, Kohji Okamoto, Takayuki Ikezoe, Kazuma Yamakawa, Seiji Madoiwa, Toshimasa Uchiyama, Hidesaku Asakura, Shinya Yamada, Shin Koga, Hiroyasu Ishikura, Takashi Ito, Toshiaki Iba, Mitsuhiro Uchiba, Kaoru Kawasaki, Noriaki Kawano, Satoshi Gando, Shigeki Kushimoto, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Toshihiko Mayumi, Hideo Wada

{"title":"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.","authors":"Yoshinobu Seki, Kohji Okamoto, Takayuki Ikezoe, Kazuma Yamakawa, Seiji Madoiwa, Toshimasa Uchiyama, Hidesaku Asakura, Shinya Yamada, Shin Koga, Hiroyasu Ishikura, Takashi Ito, Toshiaki Iba, Mitsuhiro Uchiba, Kaoru Kawasaki, Noriaki Kawano, Satoshi Gando, Shigeki Kushimoto, Yuichiro Sakamoto, Toshihisa Tamura, Kenji Nishio, Mineji Hayakawa, Takeshi Matsumoto, Toshihiko Mayumi, Hideo Wada","doi":"10.1007/s12185-024-03912-y","DOIUrl":"https://doi.org/10.1007/s12185-024-03912-y","url":null,"abstract":"This study discusses disseminated intravascular coagulation (DIC) associated with solid cancers and various vascular abnormalities, both of which generally exhibit chronic DIC patterns. Solid cancers are among the most significant underlying diseases that induce DIC. However, the severity, bleeding tendency, and progression of DIC vary considerably depending on the type and stage of the cancer, making generalization difficult. Moreover, during the process of creating these guidelines, it became apparent that despite solid cancers being a major underlying condition for DIC, there is a lack of high-quality research on DIC associated with solid cancers. Nevertheless, we developed recommendations for clinical questions (CQs) regarding the use of heparin and recombinant thrombomodulin. Additionally, statements concerning these five questions were provided. DIC associated with various vascular abnormalities, is characterized by hyperfibrinolytic activity and linked to underlying conditions such as aortic aneurysm, aortic dissection, vasculitis syndromes, and vascular malformations. These conditions must always be considered differential diagnoses when unexplained thrombocytopenia or bleeding tendencies are observed. Although no evidence was found to support the assignment of recommendation levels, three statements were made. However, traumatic vascular abnormalities have not been discussed in this context.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of late-onset sinusoidal obstruction syndrome diagnosed histologically before meeting diagnostic criteria. 一例在符合诊断标准之前经组织学诊断的晚发性窦道阻塞综合征病例。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-05 DOI: 10.1007/s12185-024-03909-7

Takashi Kuroha, Tatsuo Furukawa, Seiichi Yoshikawa, Akane Kaihatsu, Hiroki Nemoto, Hiroyuki Usuda, Toshio Yano

引用次数: 0

Iron deficiency and phlebotomy in patients with polycythemia vera. 红细胞增多症患者的铁缺乏症和抽血疗法。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-01-01 Epub Date: 2024-11-11 DOI: 10.1007/s12185-024-03868-z

Yoko Edahiro, Norio Komatsu

引用次数: 0